Cargando…
Does rifaximin offer any promise in Crohn's disease in remission and concurrent irritable bowel syndrome-like symptoms?
Microbiota plays an important role in many diseases including inflammatory bowel diseases. Inflammatory bowel disease patients can have concurrent irritable bowel syndrome symptoms similar to those associated with a flare. The potential role of gut dysbiosis in the pathogenesis of inflammatory bowel...
Autores principales: | Tocia, Cristina, Dumitru, Irina Magdalena, Alexandrescu, Luana, Petcu, Lucian Cristian, Dumitru, Eugen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793373/ https://www.ncbi.nlm.nih.gov/pubmed/33429768 http://dx.doi.org/10.1097/MD.0000000000024059 |
Ejemplares similares
-
Rifaximin for Irritable Bowel Syndrome: A Meta-Analysis of Randomized Placebo-Controlled Trials
por: Li, Jun, et al.
Publicado: (2016) -
Timing of paracentesis and outcomes in hospitalized patients with decompensated cirrhosis
por: Tocia, Cristina, et al.
Publicado: (2020) -
Usefulness of the capsule endoscopy Crohn's disease activity index in assessing the necessity of early additional treatment in patients with Crohn's disease in clinical remission
por: Miyazu, Takahiro, et al.
Publicado: (2021) -
Is rifaximin better than nonabsorbable disaccharides in hepatic encephalopathy?: A meta-analysis
por: Cheng, Junxiong, et al.
Publicado: (2021) -
Probiotics and rifaximin for the prevention of travelers’ diarrhea: A systematic review and network meta-analysis
por: Fan, Hao, et al.
Publicado: (2022)